| Subject: | FDA Issues Early Communication about Tissue Necrosis Factor Blockers and Cancers in Children and Young Adults |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 5 Jun 2008 - 11:00 am |
| The FDA has issued an Early Communication About an Ongoing Safety Review to inform healthcare professionals that the Agency is investigating a possible association between the use of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia) and the development of lymphoma and other cancers in children and young adults. The FDA is investigating approximately 30 reports of cancer in children and young adults. These reports were submitted to FDA's Adverse Event... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
